Cyclin-dependent kinases (CDKs) restrict DNA replication origin firing to once per cell cycle by preventing the assembly of prereplicative complexes (preRCs; licensing) outside of G1 phase. Paradoxically, under certain circumstances, CDKs such as cyclin E-cdk2 are also required to promote licensing. Here, we show that CDK phosphorylation of the essential licensing factor Cdc6 stabilizes it by preventing its association with the anaphase promoting complex/ cyclosome (APC/C). APC/C-dependent Cdc6 proteolysis prevents pre-RC assembly in quiescent cells and, when cells reenter the cell cycle from quiescence, CDK-dependent Cdc6 stabilization allows Cdc6 to accumulate before the licensing inhibitors geminin and cyclin A which are also APC/C substrates. This novel mechanism for regulating protein stability establishes a window of time prior to S phase when preRCs can assemble which we propose represents a critical function of cyclin E.
Introduction
DNA replication in eukaryotic cells initiates from large numbers of replication origins distributed on multiple chromosomes. A two-step mechanism regulates the initiation of DNA replication, ensuring that the entire genome is precisely duplicated in each cell cycle (Bell and Dutta, 2002; Blow and Dutta, 2005; Diffley, 2004) . In the first step, Cdc6 and Cdt1 collaborate with the origin recognition complex (ORC) to load the putative replicative helicase (Mcm2-7) into pre-RCs at replication origins. In the second step, two protein kinases, Cdc7 and the S phase CDKs, convert pre-RCs into bidirectional replisomes at each origin. DNA replication is limited to once per cell cycle because these two steps are temporally segregated: pre-RC assembly can only occur from late mitosis through G1 phase, and once cells enter S phase, pre-RCs can no longer assemble. Thus, origins that have fired once cannot be relicensed until they pass through the following mitosis.
In budding yeast, CDKs directly prevent pre-RC assembly by inhibiting the function of all of the pre-RC components thus limiting pre-RC assembly to G1 phase (Diffley, 2004) . CDKs appear to play a similar role In addition to targeting licensing inhibitors for proteolysis, the APC/C also targets the essential pre-RC assembly factor, Cdc6, for proteolysis (Petersen et al., 2000) . Coregulation of licensing inhibitors and activators, however, would make it impossible for cells to achieve a state where pre-RC components are all present but licensing inhibitors are absent. Cyclin E can either promote or inhibit pre-RC assembly, depending on context (see Diffley [2004] for discussion). Here we show that CDKs, including those containing cyclin E, promote licensing by phosphorylating a regulatory domain of Cdc6, thus preventing its degradation by the APC/C. This allows Cdc6 to accumulate before the licensing inhibitors geminin and cyclin A when quiescent cells re-enter the cell cycle. We propose a simple model to explain the positive role of cyclin E in licensing and discuss how context might also allow cyclin E to be a licensing inhibitor.
Results

CDKs Regulate Cdc6 Stability
We noticed that levels of endogenous Cdc6 protein in human tissue culture cells were significantly reduced very quickly after treatment with the CDK inhibitor, roscovitine. Other APC/C substrates including geminin, cyclin A, and cyclin B were unaffected by roscovitine during the same time interval. At the concentrations used, roscovitine should primarily inhibit CDKs (Meijer et al., 1997) . Figure 1B shows that the levels of endogenous Cdc6 were also dramatically reduced after cdk2 levels were reduced using siRNA. The effects of roscovitine on Cdc6 are seen after just 2 hr ( Figure 1A ), before any significant alteration in cell cycle distribution can occur, and depletion of cdk2 by siRNA did not affect the distribution of cells in the cell cycle (see Figure S1A in the Supplemental Data available with this article online). To determine whether the reduction in Cdc6 levels is due to changes in protein stability, we examined the rate of Cdc6 disappearance after addition of cycloheximide (CHX) to prevent new Cdc6 synthesis. Endogenous Cdc6 was relatively unstable, with a half-life of approximately 1 hr based on initial rates of disappearance, and became even more unstable after roscovitine treatment, with a half-life significantly less than 1 hr ( Figure 1C) . A similar decrease in half-life was seen after depletion of either cyclins E1 and E2 or cdk2 (Figure 
S1B
). These experiments indicate that CDK inhibition reduces Cdc6 protein levels at least in part by destabilizing the Cdc6 protein.
Overexpression of cyclin E ( Figure 1D ) or cyclin A ( Figure S3A ) caused an increase in levels of cotransfected Cdc6 tagged with the HA epitope (HA-Cdc6). This accumulation of Cdc6 was blocked by roscovitine, suggesting that CDK catalytic activity is required for Cdc6 accumulation ( Figure 1D) . Cyclin E overexpression dramatically stabilized HA-Cdc6, increasing its half-life to far greater than 3 hr ( Figure 1E ). Because transfected Cdc6 can be regulated differently from the endogenous Cdc6 (Alexandrow and Hamlin, 2004), we cotransfected cells with a cell-surface marker (CD20) which allowed us to specifically purify transfected cells. In these purified cells, endogenous Cdc6 levels were significantly increased after cotransfection with myccyclin E ( Figure 1F ). This effect was enhanced by cotransfection of myc-cyclin E with HA-cdk2. Figure S1A shows that overproduction of cyclin E had little or no effect on cell cycle distribution. As with the roscovitine treatment, myc-cyclin E with or without HA-cdk2 had no effect on levels of other APC/C substrates such as cyclin A or cyclin B ( Figure 1F ). Taken together, these experiments indicate that the stability of both endogenous and transfected Cdc6 is regulated by cyclin E-cdk2. We examined the effects of modulating CDK activity on mutant Cdc6 proteins. Overexpression of myccyclin E increased the levels of both HA-Cdc6 and endogenous Cdc6 but did not affect the levels of HACdc6⌬NT ( Figure 2B ), a version of Cdc6 lacking the entire NTD, indicating that the NTD is required for CDKs to modulate Cdc6 stability. We constructed mutant versions of Cdc6 in which the three known CDK-phosphorylated serines were replaced with either alanine (AAA) to mimic the unphosphorylated state or aspartic acid (DDD) to mimic the phosphorylated state. Expression of these mutant proteins had no effect on the distribution of cells in the cell cycle ( Figure S2 ). The DDD mutant was expressed at levels higher than the wild-type protein, while the AAA mutant was expressed at levels lower than the wild-type protein ( Figure 2C ). The DDD mutant was significantly more stable than the wild-type protein after CHX addition ( Figure 2D) . Moreover, the levels of both wild-type HA-Cdc6 and endogenous Cdc6 but not the DDD mutant were sensitive to roscovitine treatment ( Figure 2E ). The unphosphorylatable AAA mutant was destabilized even further, probably because roscovitine activates the APC/C (Listovsky et al., 2000) . Finally, Figure 2F shows that, in contrast to wildtype Cdc6, both the AAA and DDD mutants were unaffected by cyclin E overexpression together, indicating that cyclin E regulates the stability of Cdc6 by direct phosphorylation. Figure 3B ). Cdh1 overexpression also reduced AAA HA-Cdc6 levels but had no effect on the DDD mutant ( Figure 3B ). To examine this in more detail, the HA-Cdc6 constructs were cotransfected with tetracycline-inducible mycCdh1 constructs. Transfections were adjusted so the initial levels of mutant proteins were similar. After accumulation of the HA-Cdc6 proteins, doxycycline was added to induce myc-Cdh1. This induced rapid degradation of wild-type and the AAA mutant but not the DDD mutant, which remained at high levels after Cdh1 induction ( Figure 3C ). Even when targeted to the nucleus with the 3XNLS cassette, the DDD mutant was resistant to Cdh1-dependent degradation ( Figure S3H ). Conversely, reduction of Cdh1 by siRNA significantly stabilized wild-type HA-Cdc6 but had no effect on the already stabilized DDD mutant ( Figure 3D ). Figure 4A shows that polyubiquitylated forms of the wild-type but not DDD Cdc6 were detected following expression of Cdh1 and His-tagged ubiquitin, indicating that, in contrast to the wild-type protein, the DDD mutant is not polyubiquitylated in vivo. Thus, the wild-type and AAA mutant are APC/C targets, but the DDD mutant is resistant to APC/C -mediated degradation.
Stabilization Is Mediated by CDK
We next examined the degradation of an N-terminal Cdc6 fragment in concentrated extracts from quiescent cells (Rape and Kirschner, 2004) . Wild-type Cdc6 was rapidly degraded in these extracts whereas the DDD mutant as well as a construct in which the Cdc6 destruction box was mutated (⌬DB) were considerably stabilized ( Figure 4B ), indicating that the DDD mutant is resistant to APC/C-dependent proteolysis in vitro. We used affinity-purified APC/C from quiescent cells in a cell-free system to examine polyubiquitylation of biotinylated peptides spanning the destruction boxes in Cdc6. Polyubiquitylated forms of the Cdc6 peptide could be readily detected when incubated in the presence of the complete system, and this was greatly reduced when the E2 enzyme (UbcH10) was omitted from the reaction ( Figure 4C ). However, when the Cdc6 peptide was phosphorylated on Ser54 and Ser74, it was not polyubiquitylated in parallel reactions. Together, these results indicate that phosphorylation of the Cdc6 NTD by CDKs prevents its proteolysis by preventing APC/C-dependent polyubiquitylation. Finally, Cdh1 could be detected in HA immunoprecipitates with either wild-type or AAA HA-Cdc6 but not DDD HA-Cdc6 ( Figure 4D ). Cdh1 coimmunoprecipitated with wild-type but not AAA HA-Cdc6 always appears as a doublet. The reason for this is currently unknown. We propose the inability of DDD Cdc6 to interact with APC/C accounts for its resistance to APC/C-mediated proteolysis.
CDK-Dependent Stabilization Allows Early Cdc6 Accumulation
As shown above, APC/C-dependent proteolysis of Cdc6 is modulated by CDK phosphorylation of the Cdc6 NTD. In trying to understand why this elaborate regulatory mechanism exists, we were struck by the finding that cyclin E plays a positive, essential role in licensing specifically when quiescent cells reenter the cell cycle (Geng et al., 2003) and that cyclin E cooper-ates with Cdc6 to stimulate licensing in vitro (Coverley et al., 2002) . We considered that phosphorylation of the Cdc6 NTD by cyclin E-cdk2 might promote Cdc6 stabilization prior to the inactivation of the APC/C by cyclin A (Sorensen et al., 2000) . This would ensure that, in cells reentering the cell cycle, Cdc6 would accumulate before the licensing inhibitors geminin and cyclin A.
To assess the feasibility of this idea, we examined the reaccumulation of endogenous proteins after serum-starved cells were stimulated to reenter the cell cycle. Cdc6 as well as Cdt1, geminin, Cdc20, and cyclin A were absent after serum starvation (t = 0, Figure 5A ). Endogenous Cdc6 and Cdt1 both appeared approximately 10 hr after serum addition, coincident with the loading of Mcm6 onto chromatin. This was 3-4 hr earlier than the appearance of other APC/C substrates, geminin, cyclin A, and Cdc20, consistent with the hypothesis.
Two predictions of this model are that Cdc6 appearance should coincide with appearance of cyclin E kinase activity and that Cdc6 should be quantitatively phosphorylated in the NTD. To test the first prediction, cyclin E and cyclin A immunoprecipitates made from extracts of cells released from quiescence for various times were assayed for histone H1 kinase activity. Although cyclin E protein was present in the serumstarved cells, there was little or no associated H1 kinase activity (Figure 5B ), perhaps due to the presence of CDK inhibitors. Cyclin E-associated histone H1 kinase activity first appeared approximately 10 hr after serum stimulation, coinciding with the appearance of Cdc6 protein and preceding the appearance of cyclin A-associated kinase activity by 4 hr.
Using a phospho-specific antibody, Figure 5B shows that as soon as Cdc6 appears, phospho-ser54 could be detected. Treatment of extracts with λ phosphatase completely eliminated recognition of endogenous and HA-Cdc6 by the phospho-specific antibody (but not anti-Cdc6 antibody) in both immunoblots and immunoprecipitations ( Figure 5C ). Figure 5D shows that this phospho-specific antibody can quantitatively deplete Cdc6 from extracts from either exponentially growing cells or serum-starved cells which had been serum stimulated for 10 hr (when Cdc6 first appears). Thus, upon reentry into the cell cycle, Cdc6 accumulates with cyclin E-associated kinase activity and is quantitatively phosphorylated on at least one of the residues implicated in its stabilization. Figure 5E shows that constitutively expressed wildtype HA-Cdc6 accumulates approximately 10 hr after serum stimulation, coincident with the endogenous Cdc6 but before cyclin A ( Figure 5E ). Accumulation of the AAA mutant was delayed 2-4 hr relative to the endogenous protein and paralleled the appearance of cyclin A, while the DDD mutant accumulated several hours earlier than the endogenous protein. These experiments, taken with previous results, support the idea that Cdc6 is stabilized by cyclin E-cdk2 phosphorylation before other APC/C targets can accumulate upon cell cycle reentry.
Cdc6 Stabilization Promotes Pre-RC Assembly
To determine whether this mechanism can contribute to the ability of Cdc6 to support licensing, we needed to develop licensing assays that would allow us to examine the functionality of Cdc6 mutants in the absence of endogenous Cdc6. We utilized the fact that quiescent T98G cells lack both Cdc6 and Cdt1. Figure 6A shows that wild-type and AAA mutant HA-Cdc6 were unable to accumulate in quiescent cells, while the DDD mutant (as well as the Cdc6 destruction box mutant, ⌬DB- Figure 6B) ., 2002) . The difference between our results is likely due to higher expression levels from the adenovirus vector. To extend our findings, we serum-stimulated quiescent cells in the presence of roscovitine, which prevents the accumulation of endogenous Cdc6 and Cdt1, presumably in part by interfering with E2F activation ( Figure 6E ). Ectopic expression of Cdt1 was sufficient to promote its accumulation; however, neither wild-type nor the AAA mutant HA-Cdc6 could accumulate under these conditions ( Figure 6E ). Figure 6F shows that these Cdc6 constructs were also unable to act with Cdt1 to support Mcm2-7 loading significantly above background levels. By contrast, the DDD mutant accumulated efficiently upon serum addition in the presence of roscovitine ( Figure 6E ) and could support significant Mcm2-7 loading ( Figure 6F) . Therefore, only the DDD mutant can efficiently accumulate and support licensing in the presence of active APC/C.
To examine the role of cyclin E in promoting Cdc6 stabilization and licensing during G1 phase, we used siRNA to deplete cyclins E1 and E2. Figure S5 shows that endogenous Cdc6 levels drop significantly a few hours after release from a nocodazole arrest consistent with previous work (Mendez and Stillman, 2000), presumably reflecting APC/C-dependent proteolysis. Depletion of cyclins E1 and E2 from nocodazole-arrested cells prevented the reaccumulation of Cdc6 during the subsequent G1 phase after release from the nocodazole arrest ( Figure S5 ). This delay could have been a direct effect on Cdc6 stability or an indirect effect on Cdc6 transcription during G1 phase. So, we examined the effect of cyclin E depletion on accumulation of tetracycline-inducible Cdc6. Cyclins E1 and E2 were depleted in nocodazole-arrested cells and doxycycline was added upon release from the nocodazole arrest. Figure 6G shows that the accumulation of wild-type HA-Cdc6 was significantly delayed in the absence of cyclin E. By contrast, the accumulation of the DDD mutant was unaffected by cyclin E knockdown ( Figure 6H) .
To examine the importance of cyclin E-dependent stabilization of Cdc6 on licensing, we used siRNA to deplete endogenous Cdc6 in nocodazole-arrested cells. Figures 6I and 6J show that this prevented loading of Mcm6 onto chromatin after release from the nocodazole arrest. We next examined the effects of cyclin E depletion on the capacity of tetracycline-inducible, siRNA-resistant Cdc6 constructs to promote licensing. Figure 6K shows that Mcm6 loading by wild-type Cdc6 was significantly delayed after depletion of cyclin E (compare solid gray and black bars). Again, by contrast, the DDD mutant showed no delay in licensing after cyclin E depletion ( Figure 6L ). Therefore, cyclin E contributes to licensing during G1 phase by stabilizing the Cdc6 protein.
Discussion
We propose a model to resolve the paradoxical situation whereby Cdc6, an essential pre-RC component, as well as geminin and cyclin A, pre-RC inhibitors, are all targeted for degradation by the APC/C (Figure 7) . During quiescence, the highly active APC/C ensures that Cdc6 as well as geminin and cyclin A are absent from cells. The absence of Cdc6 contributes to preventing inappropriate pre-RC assembly in quiescence. When cells are stimulated to reenter the cell cycle, E2F-dependent transcription is activated, in part, by cyclin E-cdk2. Neither geminin nor cyclin A can accumulate initially because the APC/C is active; however, cyclin E, which is an E2F target but not an APC/C substrate, can accumulate during this period. Cyclin E-cdk2 phosphorylates the Cdc6 NTD, specifically preventing Cdc6 degradation via the APC/C, allowing Cdc6 to accumulate before geminin and cyclin A. Because Cdt1 is an E2F target but not an APC/C substrate, it can accumulate together with Cdc6. Later in G1 phase, the APC/C becomes inactivated, allowing the licensing inhibitors geminin and cyclin A to accumulate. Thus, Cdc6 stabilization ensures that all of the essential pre-RC components are present for a window of time in late G1 phase to allow licensing. Then, as cells enter S phase, this window is closed by the accumulation of licensing inhibitors.
Our results describe a novel mechanism for con- 
Total Cell Extracts and Chromatin Fractionation
To prepare total cell extracts, cells were lysed in EBC buffer (50 mM Tris [pH 7.5], 120 mM NaCl, 0.5% NP-40, 1 mM EDTA) containing 1 mM DTT, 5 g/ml Leupeptin, 2 g/ml Aprotinin, 0.1 mM PMSF, 10 mM β-Glycerophosphate, 1 mM NaF, and 0.1 mM Na 3 VO 4 , incubated for 20 min on ice, sonicated briefly, and lysates were cleared by centrifugation for 10 min at 20,000 rpm. For dephosphorylation of total cell extracts, lysates were prepared using EBC buffer without phosphatase inhibitors and incubated with λ phosphatase (New England BioLabs) for 15 min at 37°C. To obtain chromatinenriched fractions, cells were separated into Triton X-100-soluble and -insoluble fractions essentially as described (Ballabeni et al., 2004) . Briefly, cells were lysed in cytoskeleton (CSK) buffer (10 mM PIPES [pH 6.8], 100 mM NaCl, 1.5 mM MgCl 2 , 300 mM sucrose), containing 0.5% Triton X-100, 1 mM ATP, 1mM DTT, 5 g/ml Leupeptin, 2 g/ml Aprotinin, and 0.1 mM PMSF for 20 min on ice. Lysed cells were then centrifuged for 4 min at 3200 rpm to obtain the soluble fraction. The pellet was washed once with CSK buffer for 5 min on ice, centrifuged for 4 min at 3200 rpm, and resuspended in 2× Laemmli Sample Buffer, then boiled for 3 min and sonicated for 10 s.
Immunoblotting, Immunoprecipitation, and Kinase Assays
Immunoblotting and immunoprecipitations were done as described earlier (Mailand et al., 2000) . For immunodepletion of Ser54-phos-phorylated Cdc6, total cell extracts were subjected to three successive rounds of immunoprecipitation with phospho-Ser54 antibody or preimmune rabbit serum for 1 hr at 4°C on an end-overend rotator. Measurements of cyclin E-and A-associated Histone H1 kinase activities were done exactly as described (Mailand et al., 2000) .
Immunofluorescence
Cells grown on glass coverslips were fixed in ice-cold 1:1 (v/v) Methanol:Acetone, and immunostained with antibodies specified in figure legends and secondary Alexa Fluor 594 reagents (Molecular Probes). To detect chromatin bound Mcm6, cells were washed with CSK buffer once, extracted with CSK buffer containing 0.5% Triton X-100, 1mM DTT, 5 g/ml Leupeptin, 2 g/ml Aprotinin, and 0.1 mM PMSF for 5 min at room temperature and washed again in CSK buffer before fixation. Cells were visualized using a Zeiss 510 laserscanning microscope mounted on Axioplan 2 (Zeiss). 
Ubiquitination and Degradation Assays
Purification of CD20-Positive Cells
Transfected cells expressing the CD20 surface marker were isolated with Dynabeads (Dynal Biotech) according to the manufacturers instructions. Briefly, cells transfected at a 1:10 ratio with pCMV-CD20 were collected in PBS containing 0.1% EDTA, centrifuged and resuspended in PBS containing 0.1% BSA, and incubated with 25 l Pan Mouse IgG Dynabeads coated with monoclonal CD20 antibody for 60 min at 4°C on an end-over-end rotator. Bound cells were washed three times using a magnetic rack and processed for total cell extract preparation or chromatin fractionation.
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